{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:04:11Z","timestamp":1761523451860},"reference-count":39,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2001,12,20]],"date-time":"2001-12-20T00:00:00Z","timestamp":1008806400000},"content-version":"vor","delay-in-days":172,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Internal Medicine"],"published-print":{"date-parts":[[2001,7]]},"abstract":"<jats:p>O\u2019Dwyer ME, Druker BJ (Oregon Health Sciences University, Portland, USA). Chronic myelogenous leukaemia \u2013 new therapeutic principles. <jats:italic>J. Intern Med<\/jats:italic> 2001;<jats:bold> 250:<\/jats:bold> 3\u20139<\/jats:p><jats:p>The deregulated tyrosine kinase activity of the BCR\u2010ABL fusion protein is the cause of malignant transformation in almost all cases of chronic myelogenous leukaemia (CML), making BCR\u2010ABL an ideal target for pharmacological inhibition. Signal transduction inhibitor (STI571) (formerly CGP57 148B), is an ABL specific, tyrosine kinase inhibitor. In preclinical studies, it has been shown to selectively kill BCR\u2010ABL expressing cells, both <jats:italic>in\u2010vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic>. The results of clinical studies to date are highly encourageing and STI571 promises to be an important addition to the therapy of CML.<\/jats:p>","DOI":"10.1046\/j.1365-2796.2001.00823.x","type":"journal-article","created":{"date-parts":[[2003,3,12]],"date-time":"2003-03-12T06:13:44Z","timestamp":1047449624000},"page":"3-9","source":"Crossref","is-referenced-by-count":37,"title":["Chronic myelogenous leukaemia \u2013 new therapeutic principles"],"prefix":"10.1111","volume":"250","author":[{"given":"Michael E.","family":"O'Dwyer","sequence":"first","affiliation":[]},{"given":"Brian J.","family":"Druker","sequence":"additional","affiliation":[]}],"member":"311","published-online":{"date-parts":[[2001,12,20]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199904293401706"},{"key":"e_1_2_5_3_2","unstructured":"Anonymous SEER.Cancer Statistics Review 1973\u201390. Bethesda 1993; NCI I.44."},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9343(96)00061-7"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/243290a0"},{"key":"e_1_2_5_6_2","first-page":"1497","article-title":"A minute chromosome in human chronic granulocytic leukemia","volume":"132","author":"Nowell PC","year":"1960","journal-title":"Science"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/315550a0"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.2408149"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.2406902"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/344251a0"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-131-3-199908030-00008"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.1.62"},{"key":"e_1_2_5_13_2","first-page":"1517","article-title":"An evidence\u2010based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology [see comments]","volume":"94","author":"Silver RT","year":"1999","journal-title":"Blood"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199804023381405"},{"key":"e_1_2_5_15_2","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.V86.5.2041.bloodjournal8652041","article-title":"Graft versus leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia [see comments]","volume":"86","author":"Kolb HJ","year":"1995","journal-title":"Blood"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.3.756"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1099-0739(199802)12:2<121::aid-aoc685>3.0.co;2-q"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.10.3515"},{"key":"e_1_2_5_19_2","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1182\/blood.V62.3.689.689","article-title":"Leukocyte interferon\u2010induced myeloid cytoreduction in chronic myelogenous leukaemia","volume":"62","author":"Talpaz M","year":"1983","journal-title":"Blood"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199403243301204"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)92596-1"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.3.906.906"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/89.21.1616"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199707243370402"},{"key":"e_1_2_5_25_2","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1182\/blood.V94.11.3668","article-title":"Interferon\u2010alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure","volume":"94","author":"Hehlmann R","year":"1999","journal-title":"Blood"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.3263702"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI9083"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0596-561"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.9.3691"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002800051001"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.12.4947"},{"key":"e_1_2_5_32_2","first-page":"1661","article-title":"Selective inhibition of cell proliferation and BCR\u2010ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190, 000\u2003BCR\u2013ABL protein by a tyrosine kinase inhibitor (CGP\u201357148)","volume":"4","author":"Beran M","year":"1998","journal-title":"Clin Cancer Res"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.2.163"},{"key":"e_1_2_5_34_2","unstructured":"DrukerBJ TalpazM RestaDet\u2003al.Clinical efficacy and safety of an ABL specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia.Blood1999;94Suppl: 368a."},{"key":"e_1_2_5_35_2","first-page":"4a","article-title":"Activity of an ABL specific tyrosine kinase inhibitor in patients with BCR\u2010ABL positive acute leukemias, including chronic myelogenous leukemia in blast crisis","volume":"19","author":"Talpaz M","year":"2000","journal-title":"Proc ASCO"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.9.3195"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.5.1758.005a41_1758_1766"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.3.1070"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.11.3498"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401874"}],"container-title":["Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2796.2001.00823.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2796.2001.00823.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T00:34:45Z","timestamp":1697330085000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2796.2001.00823.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,7]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,7]]}},"alternative-id":["10.1046\/j.1365-2796.2001.00823.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2796.2001.00823.x","archive":["Portico"],"relation":{},"ISSN":["0954-6820","1365-2796"],"issn-type":[{"value":"0954-6820","type":"print"},{"value":"1365-2796","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,7]]}}}